Metabolic Acidosis - Pipeline Insight, 2024

This “Metabolic Acidosis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Metabolic Acidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metabolic Acidosis Understanding

Metabolic Acidosis: Overview

Metabolic acidosis is primary reduction in bicarbonate, typically with compensatory reduction in carbon dioxide partial pressure. Metabolic acidosis is a disturbance of the body acid-base balance in which there is excessive acidity of the blood. Metabolic acidosis can occur as a result of many different diseases, such as kidney failure, poisoning, diabetic ketoacidosis (DKA), and shock. Symptoms and signs include nausea and vomiting, lethargy, and hyperpnea. A metabolic acidosis can be caused by three major mechanisms: increased acid production, bicarbonate loss, and decreased renal acid excretion. Diagnosis of metabolic acidosis is clinical and with arterial blood gas (ABG) and serum electrolyte measurement. There are no FDA-approved therapies for long-term treatment of metabolic acidosis. Treatment is directed at the underlying cause. Alkali therapy and diet also helps in balancing the acid amount.

Metabolic Acidosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metabolic Acidosis pipeline landscape is provided which includes the disease overview and Metabolic Acidosis treatment guidelines. The assessment part of the report embraces, in depth Metabolic Acidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metabolic Acidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Metabolic Acidosis R&D. The therapies under development are focused on novel approaches to treat/improve Metabolic Acidosis.

Metabolic Acidosis Emerging Drugs Chapters

This segment of the Metabolic Acidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metabolic Acidosis Emerging Drugs

Veverimer (TRC101): Tricida Veverimer is a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). It binds to hydrochloric acid in the gastrointestinal tract and remove it from the body through excretion in the feces. Veverimer is in Phase III clinical studies to evaluate the effect of TRC101 on the progression of chronic kidney disease (CKD) and to evaluate the safety profile of TRC101 in CKD patients with metabolicacidosis.

Metabolic Acidosis: Therapeutic Assessment

This segment of the report provides insights about the different Metabolic Acidosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Metabolic Acidosis

There are approx. 5+ key companies which are developing the therapies for Metabolic Acidosis. The companies which have their Metabolic Acidosis drug candidates in the most advanced stage, i.e. Phase III include, Tricida.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Metabolic Acidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metabolic Acidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Metabolic Acidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metabolic Acidosis drugs.

Metabolic Acidosis Report Insights

• Metabolic Acidosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metabolic Acidosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metabolic Acidosis drugs?
• How many Metabolic Acidosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metabolic Acidosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Metabolic Acidosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metabolic Acidosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ardelyx
• Tricida
• Haim Bio
• Pharmazz

Key Products

• RDX020
• Veverimer (TRC101)
• Aldehyde dehydrogenase inhibitor
• PMZ 2123

This product will be delivered within 2 business days.